Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award
Date:10/28/2008

Fourth Innovation Award for Abbott in Six Years Recognizes Breakthrough

Treatment for the Most Common Form of Heart Disease

ABBOTT PARK, Ill., Oct. 28 /PRNewswire/ -- Abbott today announced it has received a 2008 Chicago Innovation Award for its XIENCE V(TM) Everolimus Eluting Coronary Stent System. Based on the product's innovative design and strong clinical data, the next-generation drug eluting stent represents a significant advance in the treatment of coronary artery disease.

Abbott's XIENCE V stent was approved by the United States Food and Drug Administration (FDA) and launched in July 2008, providing a new treatment option for the nearly 13 million Americans with coronary artery disease, the leading cause of death for both men and women in the United States. Stents are designed to prop open an artery that has become clogged by plaque build-up and restore blood flow to the heart. A drug eluting stent releases a medication (everolimus, in the case of XIENCE V) in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE V is the only drug eluting stent to demonstrate superiority over the previous market-leading drug eluting stent in two randomized, pivotal clinical trials -- and XIENCE V has become the market-leading drug eluting stent in just three months since launch.

This is the fourth Chicago Innovation Award that Abbott has received in six years. Most recently, the company's m2000(TM) molecular diagnostic instrument in combination with the RealTime HIV-1 viral load test received the honor in 2007. In 2005, the company's PathVysion(TM) breast cancer test received the honor, and in 2003, HUMIRA(TM), the first human monoclonal antibody drug for rheumatoid arthritis, won the award.

"At Abbott, we are proud to be in the business of developing innovative treatments that improve and save lives," said Miles D. White, chairman and chief executive officer, Abbott. "Receivi
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
2. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
3. Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
7. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
8. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
9. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
10. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
11. PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Treatment With Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... and plant-derived compounds. BCC Research reveals in its new report that the ... market defines the category and generates the most market demand. , BCC ...
(Date:9/2/2015)... SAN FRANCISCO, Calif. , Sept. 2, 2015 /PRNewswire/ ... that Bonnie H. Anderson , president and chief ... Healthcare Conference on Wednesday, September 16, 2015 at 10:30 ... . The live audio webcast and ... http://investor.veracyte.com . The webcast will be available shortly after ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical imaging ... vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ONYX ... clinical decisions with simultaneous access to high precision medical images and electronic health ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... BioTrends Research Group, Inc. finds that with the introduction of ... treatment of multiple sclerosis (MS), neurologists anticipate major shifts in ... launch of Gilenya, trial and uptake of Extavia, a DMA ... due to the perception that Extavia is a "me too" ...
... A team of Bioengineers in the United States have ... to produce ethanol. The research, published in Biotechnology ... can be combined for strain improvement, a positive development ... research on Zymomonas mobilis, a bacterium noted for its ...
... Agrivida, Inc. today announced a collaboration with ... will provide low-cost sugars for a variety of ... Syngenta licenses to Agrivida access to crop technology ...   Agrivida will bolster its existing ...
Cached Biology Technology:With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Bioengineers develop bacterial strain to increase ethanol biofuel production 2Agrivida Announces Collaboration With Syngenta Ventures to Deliver Low-Cost Sugars for Cellulosic Biofuels and Biochemicals 2
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... concern for enterprises, banks, government organizations, telecommunication and hospitals ... assets. Keys, identity badges, and numeric keypads are used ... the structure of palm and fingers of an individual, ... Hand geometry scanners with infrared light and reflectors can ...
(Date:9/2/2015)... Sept. 2, 2015 Security of data ... enterprises, banks, government organizations, telecommunications, hospitals, as well ... were previously being used to prevent unauthorised access. ... authentication, wherein individuals could gain access to secure ... such as hardware devices and numeric codes. However, ...
(Date:9/2/2015)... California , September 2, 2015 ... the security purpose implied in a system which ... geometry, voice, signature, iris, vein, DNA and finger ... has forced to develop such system which provides ... username, password, PIN, Patterns and tokens are vulnerable ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... BioScience®, Inc., (OTCBB: PMBS) announced today that they will ... Denver, Colorado between June 23- 26, 2012. ... implementing a media blitz for LipiGesic® M, which has ... found to be a safe, highly effective, first-line therapy ...
... SAN DIEGO, June 11, 2012 /PRNewswire-iReach/ -- ... that Dr. Prediman K. (PK) Shah has joined it,s ... at Cedar Cedars-Sinai Professorial Series, and Director of the ... the Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center ...
... is available in German . ... a very large group of natural nitrogen-containing compounds with ... of plant-produced alkaloids have strong pharmacological effects, and are ... caffeine, nicotine, morphine, quinine, strychnine, atropine and cocaine. Atropine, ...
Cached Biology News:PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDS's Marketplace 2012 Trade Convention 2PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDS's Marketplace 2012 Trade Convention 3FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board 2FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board 3How plants make cocaine 2How plants make cocaine 3
RAT ANTI MOUSE JAM-2 Immunogen: Recombinant soluble JAM-2...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
... complementary RNA Spikes for the normalization and ... array printing and for protocol assessment and ... hybridization stringency and background. Normalize Cy3 and ... Oligo Spots, and complementary RNA Spikes for ...
Kit for Detection of Mitochondrial Membrane Potential...
Biology Products: